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Abstract
Chronic mucus hypersecretion (CMH) is prevalent in both asthma and chronic obstructive 
pulmonary disease (COPD) and is associated with more severe symptoms. Recently, we identified 
several microRNAs (miRNAs) associated with CMH in COPD. In this study, we extended our 
analysis to CMH in asthma.
Using small RNA sequencing and RNA sequencing profiles of bronchial biopsies from 65 
asthmatic patients, we identified 17 miRNAs associated with CMH in asthma. When comparing 
them to our previously published dataset in COPD, we found a positive association of miR-31-5p 
with CMH in both diseases. MiR-31-5p was negatively correlated with multiple predicted targets, 
including ST3GAL2, PITPNM2, and ARHGEF15 which were also associated with CMH. Gene set 
enrichment analysis revealed the enrichment of MUC5AC-associated gene set and CMH-
associated gene set in COPD among CMH-associated genes in asthma.
Our findings suggest CMH in asthma and COPD share common regulatory mechanisms mediated, 
at least in part, by miR-31-5p. This study provides novel insights that could contribute to the 
development of CMH-targeted therapy that efficiently benefits both asthma and COPD patients.
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To the Editor:
Chronic mucus hypersecretion (CMH) is prevalent in both asthma1 and chronic obstructive 
pulmonary disease (COPD)2 and is associated with more severe symptoms.2–5 Mucus is composed 
of heavily glycosylated proteins called mucins, of which MUC5AC and MUC5B are the main 
mucins involved in asthma6,7 and COPD.8,9 As post-transcriptional regulators of gene expression, 
microRNAs (miRNAs) play a role in various human diseases.10 Recently, we identified several 
miRNAs associated with CMH in COPD.11 In the present study, we extended our analysis to CMH 
in asthma which is important as it would be efficient to develop the same therapy targeting CMH 
in both diseases if they share common regulatory mechanisms.
Small RNA sequencing and RNA sequencing was performed on bronchial biopsies from 
65 asthmatic patients.12 The patients either had never been treated with inhaled corticosteroid 
(ICS), had stopped ICS treatment for 6-8 weeks prior to the bronchoscopy, or were current ICS 
users. The study approach is illustrated in Fig.1A and detailed methods are described in the Online 
Repository. Patient characteristics are presented in Table E1.
We first compared miRNA profiles between ICS-naïve asthmatic patients with (n=6) and 
without CMH (n=14) using linear regression adjusting for age, gender, smoking status and library 
preparation batch. We identified 17 differentially expressed miRNAs associated with CMH 
(FDR<.05; Fig.1B and E1). In  asthmatic patients with CMH, the expression of miR-31-5p, miR-
152-3p, and miR-155-5p was higher, while the expression of miR-15b-3p, miR-15b-5p, miR-16-2-
3p, miR-25-3p, miR-92a-3p, miR-106b-3p, miR-185-5p, miR-223-3p, miR-3615, miR-423-5p, 
miR-425-5p, miR-451a, miR-484 and miR-486-5p was lower compared to  patients without CMH. 
The most strongly up-regulated miRNA was miR-31-5p (4.11 fold) and the most strongly down-
regulated one was miR-486-5p (9.47 fold) (Table E2). Interestingly, miR-31-5p was previously 
also found to be associated with CMH in COPD, with the same direction of effect.11 When 
including the current ICS users in the analysis, none of the miRNAs was significantly associated 
with CMH, reflecting an evident influence of corticosteroids on expression of these miRNAs.
Next, we identified CMH-associated mRNAs with the same approach. Expression of 
MUC5AC, but not MUC5B, was significantly higher in the asthmatic patients with versus those 
without CMH (P<.0001, Fig.1C). When corrected for multiple tests (FDR<.05), we identified 2 
mRNAs associated with CMH, i.e. Chromosome 3 Open Reading Frame 70 (C3orf70) and 
phosphatidylinositol transfer protein membrane associated 2 (PITPNM2). Using Gene Set 
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associated genes in COPD11 were enriched among the genome-wide mRNAs, ranked based on the 
strength (fold change) of their association with CMH in ICS-naïve asthma patients as determined 
by linear regression. As expected, we found significant enrichment (P<.001) of both gene sets 
among the ranked list (Fig.1C-1D), suggesting that MUC5AC is associated with CMH and that 
CMH in asthma and COPD share common regulatory mechanisms.
We then assessed whether any of the CMH-associated miRNAs were correlated with 
MUC5AC or MUC5B using matched small RNA-sequencing and RNA-sequencing profiles in all 
asthmatic patients (n=65) (Table E3). There was a significant positive correlation between miR-
16-2-3p and MUC5B (p=0.02) and a trend of positive correlation between miR-31-5p and 
MUC5AC (p=0.06). Similar to asthma, miR-31-5p was not correlated with MUC5B in the COPD 
dataset. MUC5AC expression was not measured by the microarray we used for the COPD dataset 
(Affymetrix HuGene ST1.0v1), however, we previously showed that MUC5AC-associated core 
genes were enriched among miR-31-5p-correlated genes11 suggesting that miR-31-5p regulates 
CMH, at least in part, via modulation of MUC5AC synthesis. 
Since we found miR-31-5p to be associated with CMH in both asthma and COPD, we 
assessed correlations between miR-31-5p and genome-wide mRNA expression regardless of their 
association with CMH using matched small RNA-sequencing and RNA-sequencing profiles in all 
asthmatic patients (n=65). As miRNAs inhibit translation of their mRNA targets partly by 
inducing mRNA degradation, we expected the mRNA targets of miR-31-5p to be negatively 
correlated with this miRNA. Spearman’s correlation coefficient revealed 890 genes of which 
expression levels were negatively correlated with miR-31-5p (FDR<.05). Among these 890 
negatively correlated genes, 48 were predicted miR-31-5p targets according to TargetScan or 
miRDB or both (Fig.2A). Next, we applied the same approach on our previously published COPD 
bronchial biopsy dataset11 which resulted in 62 predicted targets negatively correlated with miR-
31-5p (Fig.2A). When combining these 48 and 62 predicted targets, we found 17 overlapping 
negatively correlated predicted targets of miR-31-5p in asthma and COPD (Fig.2A, Table E4). To 
identify common mechanisms in which these 17 genes may be involved, we performed GO 
Enrichment Analysis14,15 but found no significant enrichment of GO terms.
Interestingly, of these 17 miR-31-5p correlated targets, ST3 Beta-Galactoside Alpha-2,3-
Sialyltransferase 2 (ST3GAL2), PITPNM2 and Rho guanine nucleotide exchange factor 15 
(ARHGEF15) showed significantly lower expression levels in patients with CMH compared to 
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we found that the negative correlation between miR-31-5p and ARHGEF15 remained nominally 
significant (p=.03), while there was a trend for a negative correlation with ST3GAL2 (p=.05) and 
PITPNM2 (p=.08). ST3GAL2 is a member of sialyltransferases. Previous studies showed that 
higher sialylation of airway mucins is present in bacterial infected patients with cystic fibrosis and 
with chronic bronchitis compared to non-infected patients.16 This sialylation, occurring during 
mucin biosynthesis, could influence host-microbial interaction during infection.17 Thus, ST3GAL2 
may play a role in mucin glycosylation and it is worthwhile to investigate if and how this 
contributes to CMH. Little is known about the function of PITPNM2, while ARHGEF15 is a Rho 
guanine nucleotide exchange factor specifically expressed in endothelial cells.18 Notably, all these 
17 genes are expressed in both human-derived basal epithelial cells and goblet cells, as assessed in 
our single-cell RNA sequencing profiles of bronchial brushes from 6 non-asthmatic control donors 
and 6 asthmatic donors (BioRxiv 527408).19
It is not yet conclusive whether higher miR-31-5p expression in CMH is a reflection of its 
stimulatory or protective role on mucus production. Previously, miR-31-5p expression was found 
to be slightly lower in asthmatic airway epithelial brushings compared to those of healthy controls 
but CMH status of these patients was not reported.20 Although bronchial biopsies contain various 
cell types apart from epithelial cells, we found no difference in numbers of inflammatory cells, i.e. 
T-cells, B-cells, neutrophils, macrophages, eosinophils, and mast cells, between the asthmatic 
patients with and without CMH. This suggests that these findings were not driven by infiltration of 
different inflammatory cells.12 As our data is based on miRNA-mRNA correlations, future studies 
are warranted to confirm the direct interaction and functional consequences. Furthermore, these 
miRNAs and mRNAs were identified using a relatively small sample size and the patients with 
CMH were all males (Table E1). Therefore, similar analyses performed on a larger cohort with 
equal gender distribution would strengthen these findings. Since these findings are based on 
association analyses, future functional studies are required to elucidate whether and how these 
genes and miR-31-5p directly contribute to CMH. Besides, we encourage other researchers who 
could to replicate these findings using other measurements of CMH, such as overall mucin 
concentration in sputum which is one of the important markers of CMH.9
This is the first study to propose miR-31-5p as a shared regulator of CMH in both asthma 
and COPD. We identified several mRNAs potentially targeted by miR-31-5p, including ST3GAL2, 
PITPNM2, and ARHGEF15 that were negatively associated with CMH in both diseases. These 
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contribute to the development of CMH-targeted therapy that efficiently benefits both asthma and 
COPD patients.
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FIGURE 1. MiRNAs and associated genes potentially regulate CMH. A, An overview of the 
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performed on a group of ICS-naïve asthmatic patients (n=20). Only miRNAs of >100 counts were 
shown. Dot line indicates a significance of FDR<.05. C, Enrichment of MUC5AC-associated 
genes among CMH-positively associated genes (P<.001) and higher MUC5AC expression in 
asthmatic patients with CMH vs without CMH. ****P<.0001. D, Enrichment of CMH-associated 
genes in COPD among CMH-associated genes in asthma (P<.001). Height of each bar in the 
enrichment plot represents the enrichment score of each gene in the gene set of interest.
FIGURE 2. Shared mechanisms of CMH in asthma and COPD likely modulated by miR-31-5p. 
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associated targets in all asthmatic patients (n=65). Closed circles represent expression in patients 
who have been or are currently treated with ICS. Open circles represent expression in ICS-naïve 
group. Statistics shown in the plots (r and p values) were based on all patients. Spearman 
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